Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cardiovascular diseases AND dyslipidemias AND simvastatin AND treatment outcome:

Search results

Items: 1 to 20 of 254

1.

Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.

Ferket BS, Hunink MG, Khanji M, Agarwal I, Fleischmann KE, Petersen SE.

Heart. 2017 Apr;103(7):483-491. doi: 10.1136/heartjnl-2016-310529. Epub 2017 Jan 11.

PMID:
28077465
2.

Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.

Bangalore S, Fayyad R, Messerli FH, Laskey R, DeMicco DA, Kastelein JJ, Waters DD.

Am J Cardiol. 2017 Feb 1;119(3):379-387. doi: 10.1016/j.amjcard.2016.10.037. Epub 2016 Nov 4.

PMID:
27939230
3.

L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study.

Florentin M, Elisaf MS, Rizos CV, Nikolaou V, Bilianou E, Pitsavos C, Liberopoulos EN.

Lipids. 2017 Jan;52(1):1-9. doi: 10.1007/s11745-016-4216-z. Epub 2016 Dec 2.

PMID:
27914033
4.

Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.

Izquierdo-Palomares JM, Fernandez-Tabera JM, Plana MN, Añino Alba A, Gómez Álvarez P, Fernandez-Esteban I, Saiz LC, Martin-Carrillo P, Pinar López Ó.

Cochrane Database Syst Rev. 2016 Nov 26;11:CD009462. Review.

PMID:
27888640
5.

Characterization and cholesterol management in patients with cardiovascular events and/or type 2 diabetes in the Netherlands.

Heintjes E, Kuiper J, Lucius B, Penning-van Beest F, Kutikova L, Liem A, Herings R.

Curr Med Res Opin. 2017 Jan;33(1):91-100. Epub 2016 Sep 29.

PMID:
27646783
6.

Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality.

Besseling J, Hovingh GK, Huijgen R, Kastelein JJP, Hutten BA.

J Am Coll Cardiol. 2016 Jul 19;68(3):252-260. doi: 10.1016/j.jacc.2016.04.054.

7.

Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.

Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group.

Diabetes Care. 2016 Jul;39(7):1089-100. doi: 10.2337/dc16-0024. Epub 2016 Jun 11.

8.

The effect of hypolipidemic treatment on monocyte cytokine release in different age groups of patients with type 2 diabetes and atherogenic dyslipidemia.

Krysiak R, Gdula-Dymek A, Marek B, Okopień B.

Endokrynol Pol. 2016;67(2):190-6. doi: 10.5603/EP.a2016.0021. Epub 2016 Feb 17.

9.

Intensive LDL lowering therapy for prevention of recurrent cardiovascular events: a word of caution.

Simoons ML, Deckers JW.

Eur Heart J. 2016 Feb 7;37(6):520-3. doi: 10.1093/eurheartj/ehv616. Epub 2015 Nov 3. No abstract available.

PMID:
26537621
10.

A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death.

Mesgarpour B, Gouya G, Herkner H, Reichardt B, Wolzt M.

Lipids Health Dis. 2015 Oct 24;14:131. doi: 10.1186/s12944-015-0134-y.

12.

Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.

Rosen JB, Ballantyne CM, Hsueh WA, Lin J, Shah AK, Lowe RS, Tershakovec AM.

Lipids Health Dis. 2015 Sep 4;14:103. doi: 10.1186/s12944-015-0075-5.

13.

Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials.

Thomopoulos C, Skalis G, Michalopoulou H, Tsioufis C, Makris T.

Clin Cardiol. 2015 Dec;38(12):763-9. doi: 10.1002/clc.22441. Epub 2015 Aug 18. Review.

15.

[The surprising (?) results of IMPROVE-IT].

Poli A.

G Ital Cardiol (Rome). 2015 May;16(5):281-3. doi: 10.1714/1870.20426. Italian. No abstract available.

PMID:
25994463
16.

Practical recommendations for the management of hyperlipidemia.

Fischer S, Schatz U, Julius U.

Atheroscler Suppl. 2015 May;18:194-8. doi: 10.1016/j.atherosclerosissup.2015.02.029. Review.

PMID:
25936326
17.

LDL-cholesterol lowering and renal outcomes.

Waters DD.

Curr Opin Lipidol. 2015 Jun;26(3):195-9. doi: 10.1097/MOL.0000000000000176. Review.

18.

Study CAMBIMED: Effects of changes in medication appearance on safety of antihypertensive and hypolipidemic treatments in chronic patients older than 65 years in primary health care.

Arancon-Monge JM, de-Castro-Cuenca A, Serrano-Vázquez Á, Campos-Díaz L, Díaz-Eraso M, Del Cura-González I, Polentinos-Castro E, Rodríguez-Barrientos R; Autores Colaboradores: GRUPO CAMBIMED.

BMC Public Health. 2015 Mar 4;15:211. doi: 10.1186/s12889-014-1342-5.

19.

Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics.

Ramadan WH, Kabbara WK.

Vasc Health Risk Manag. 2015 Feb 11;11:125-32. doi: 10.2147/VHRM.S79198. eCollection 2015. Review.

20.

[Low persistence of simvastatin and ezetimibe fixed combination in the lipid lowering therapy].

Simonyi G, Ferenci T.

Orv Hetil. 2015 Jan 25;156(4):141-5. doi: 10.1556/OH.2015.30085. Hungarian.

PMID:
25597318

Supplemental Content

Loading ...
Support Center